Cytosolix develops novel oral and IV derivatives that target tumor acidity to improve the efficacy of small molecule cancer therapeutics. Cytosolix's Tumor Activated Permeability System, produces weakly-acidic derivatives of known oncology drugs, that enhance the uptake by cancer cells while restricting the uptake by healthy cells, enabling